Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

Abstract Objective: To compare rates of upper gastrointestinal haemorrhage among elderly patients given selective cyclo-oxygenase-2 (COX 2) inhibitors and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Design: Observational cohort study. Setting: Administrative data from Ontario, Cana...

Full description

Saved in:
Bibliographic Details
Published inBMJ Vol. 325; no. 7365; pp. 624 - 627
Main Authors Mamdani, Muhammad, Rochon, Paula A, Juurlink, David N, Kopp, Alex, Anderson, Geoffrey M, Naglie, Gary, Austin, Peter C, Laupacis, Andreas
Format Journal Article
LanguageEnglish
Published London British Medical Journal Publishing Group 21.09.2002
British Medical Association
BMJ Publishing Group Ltd
BMJ Publishing Group LTD
BMJ Publishing Group
BMJ
EditionInternational edition
Subjects
Online AccessGet full text
ISSN0959-8138
0959-8146
1756-1833
1468-5833
1756-1833
DOI10.1136/bmj.325.7365.624

Cover

Loading…
More Information
Summary:Abstract Objective: To compare rates of upper gastrointestinal haemorrhage among elderly patients given selective cyclo-oxygenase-2 (COX 2) inhibitors and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Design: Observational cohort study. Setting: Administrative data from Ontario, Canada, used from 17 April 2000 to 31 March 2001 to identify population based, NSAID-naive cohorts of patients. Patients: Subjects aged ≥ 66 years who started taking non-selective NSAIDs (n=5391), diclofenac plus misoprostol (n=5087), rofecoxib (n=14 583), or celecoxib (n=18 908) and a randomly selected control cohort not exposed to NSAIDs (n=100 000). Main outcome measures: Rate ratios of hospital admission for upper gastrointestinal haemorrhage in each drug cohort with adjustment for potential confounders. Results: Relative to controls, the multivariate model revealed an increased short term risk of upper gastrointestinal haemorrhage for users of non-selective NSAIDs (adjusted rate ratio 4.0 (95% confidence intervals 2.3 to 6.9)), diclofenac plus misoprostol (3.0 (1.7 to 5.6)), and rofecoxib (1.9 (1.3 to 2.8)) but not celecoxib (1.0 (0.7 to 1.6)). Relative to celecoxib, significantly higher risks of upper gastrointestinal haemorrhage were observed for non-selective NSAIDs (4.4 (2.3 to 8.5)), diclofenac plus misoprostol (3.2 (1.6 to 6.5)), and rofecoxib (1.9 (1.2 to 2.8)). Relative to rofecoxib, non-selective NSAID users were at significantly higher risk of upper gastrointestinal haemorrhage (1.9 (1.0 to 3.5)). Conclusions: This population based observational study found a lower short term risk of upper gastrointestinal haemorrhage for selective COX-2 inhibitors compared with non-selective NSAIDs.
Bibliography:istex:8D23589E1F9587312C5FC61F4314AB8602F46EB0
ark:/67375/NVC-QP2P17ZM-S
local:bmj;325/7365/624
ArticleID:bmj.325.7365.624
PMID:12242172
Correspondence to: M Mamdani
href:bmj-325-624-1.pdf
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
Correspondence to: M Mamdani muhammad.mamdani@ices.on.ca
Contributors: MM, PAR, DNJ, GMA, GN, and AL designed the study; MM, DNJ, PCA, and AK performed the study. GN, PCA, and AL advised and supervised. Statistical advice was given by PCA. MM is the guarantor.
ISSN:0959-8138
0959-8146
1756-1833
1468-5833
1756-1833
DOI:10.1136/bmj.325.7365.624